Q-omics provides the consensus-scored TF profile across patient tissues and cancer cell-line models. TF expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TF is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, TF RNA expression shows 14,982 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where TF shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TF — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TF survival associations across molecular data types. TF RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TF RNA expression–survival associations across cancer types. High TF expression shows unfavorable associations in KIRC, STAD, THCA and BLCA, but favorable associations in SKCM and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TF RNA expression.
This table summarizes TF tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TF. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TF shows lower tumor expression in HNSC, COAD, THCA, BRCA, KICH and CHOL. The HNSC box plot shows higher TF RNA expression in normal versus tumor tissue (log2 FC = −2.832, t-test p < 0.001).
This table shows molecular features associated with TF in patient tissues and cancer cell lines. In patient samples, TF shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TF RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SKIN.
